Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

swissinfo.ch - Jessica Davis Plüss (text) Kai Reusser (visuals) - Basel's world-beating pharma hub fights for place in new global order
Basel's world-beating pharma hub fights for place in new global order
www.swissinfo.ch

Few cities in the world have an identity so tightly bound to an industry as Basel and pharmaceuticals. Roche and Novartis, two of the world's biggest drugmakers, loom large over the city. Walk across any bridge in the city, and you can see the…

swissinfo.ch - swissinfo.ch - Swiss pharma companies flock to North Carolina
Swiss pharma companies flock to North Carolina
www.swissinfo.ch

Mountains, waterfalls, Atlantic beaches – North Carolina's natural beauty is captivating. But that's not why Swiss companies are moving to the state. It is rather thanks to an active investment promotion policy. This policy has become all…

globenewswire.com - Zealand Pharma - Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
GlobeNewswire

Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…

chron.com - BridgeBio Pharma: Q2 Earnings Snapshot
BridgeBio Pharma: Q2 Earnings Snapshot
Chron

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Monday reported a loss of $152.2 million in its second quarter. On a per-share basis, the Palo Alto, California-based company said it had a loss of 78…

seekingalpha.com - SA Transcripts - BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
Seeking Alpha

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDT Chinmay Shukla - Senior Vice President of Strategic Finance Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer Thomas Trimarchi - CFO &…

chron.com - Molly Wilhelm - Pharma giant bets $2.3B on Houston with massive new campus
Pharma giant bets $2.3B on Houston with massive new campus
Chron

One of the nation's largest pharmaceutical companies has officially selected Houston for a massive $2.3 billion manufacturing campus. On Monday, Bristol Myers Squibb announced it had selected Generation Park in Houston for a new 'state-of-the-art…

rediff.com - Sohini Das - Indian Pharma Firms Maintain India Base, Focus on Complex US Products Amid Tariff Threat
Indian Pharma Firms Maintain India Base, Focus on Complex US Products Amid Tariff Threat
Rediff.com

Despite former US President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs, Indian pharmaceutical companies are strategically maintaining India as their primary production base while making selective…

indianexpress.com - Anonna Dutt - 'Suggestions not accepted': Bill to overhaul drugs law faces opposition from pharma, medical device sector
'Suggestions not accepted': Bill to overhaul drugs law faces opposition from pharma, medical device sector
The Indian Express

5 min read New Delhi Make us preferred source on Google A Bill to overhaul the Drugs and Cosmetics Act, 1940, currently being circulated to stakeholder ministries, is facing fierce opposition from the country's nascent medical device sector.

thehindu.com - The Hindu Bureau - Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
The Hindu

Injectable-focussed generic drugmaker Gland Pharma reported consolidated net profit for June quarter rose 47% year-on-year (YoY) to ₹317 crore. It came on a 20% YoY increase in revenue from operations to ₹1,800.3 crore. On a…

marketbeat.com - BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results
BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results
MarketBeat

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.20), FiscalAI…

marketbeat.com - BridgeBio Pharma Q2 Earnings Call Highlights
BridgeBio Pharma Q2 Earnings Call Highlights
MarketBeat

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage…

thehindubusinessline.com - AstraZeneca Pharma India Q1 profit drops to ₹37.93 crore
AstraZeneca Pharma India Q1 profit drops to ₹37.93 crore
BusinessLine

AstraZeneca Pharma India Ltd on Monday reported a 32 per cent decline in profit after tax at ₹37.93 crore in the June quarter, impacted by higher expenses. The company had posted a profit after tax of ₹55.83 crore in the corresponding…

thehindubusinessline.com - Gland Pharma net profit rises 47% to ₹317 crore in Q1
Gland Pharma net profit rises 47% to ₹317 crore in Q1
BusinessLine

Gland Pharma's consolidated net profit increased 47 per cent to ₹317 crore in the first quarter ended June 30, 2026, compared to ₹215 crore in the corresponding quarter of the previous financial year. The total revenue of the…

pehub.com - Nina Lindholm - Spain a 'value destination' for mid-market investors; Wise Equity to acquire E-Pharma Trento
Spain a 'value destination' for mid-market investors; Wise Equity to acquire E-Pharma Trento
PE Hub

A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.

marketbeat.com - Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX
Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Royal Bank of Canada boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned…

Receive a Daily briefing on Pharma Industry News

Get Started